MK-8591

• CAT Number: I007881
• CAS Number: 865363-93-5
• Molecular Formula: C12H12FN5O3
• Molecular Weight: 293.258
• Purity: 98%
• Synonyms: Islatravir;MK-8591; MK 8591; MK8591;(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-ol
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• IUPAC Name: (2R,3S,5R)-5-(6-amino-2-fluoropurin-9-yl)-2-ethynyl-2-(hydroxymethyl)oxolan-3-ol
• InChI: InChI=1S/C12H12FN5O3/c1-2-12(4-19)6(20)3-7(21-12)18-5-15-8-9(14)16-11(13)17-10(8)18/h1,5-7,19-20H,3-4H2,(H2,14,16,17)/t6-,7+,12+/m0/s1
• InChIKey: IKKXOSBHLYMWAE-QRPMWFLTSA-N
• SMILES: C#CC1(C(CC(O1)N2C=NC3=C2N=C(N=C3N)F)O)CO

MK-8591 (CAT: I007881), also known as EFdA (4′-ethynyl-2-fluoro-2′-deoxyadenosine), is a potent nucleoside reverse transcriptase inhibitor (NRTI) with antiviral activity against HIV-1. It works by inhibiting the reverse transcriptase enzyme, which is essential for the replication of the HIV virus. MK-8591 has a long half-life, allowing for once-weekly dosing, and it has shown potent antiviral activity even at low concentrations. It has demonstrated efficacy in reducing HIV viral load and maintaining viral suppression in clinical trials. MK-8591 holds promise as a potential long-acting antiretroviral therapy for HIV treatment and prevention.

Overview of Clinical Research

Islatravir is under investigation in clinical trial (NCT04233216) in Heavily Treatment-experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019).

Reference

1.Ohrui, Hiroshi, et al. "2′-Deoxy-4′-C-ethynyl-2-fluoroadenosine: a nucleoside reverse transcriptase inhibitor with highly potent activity against wide spectrum of HIV-1 strains, favorable toxic profiles, and stability in plasma." Nucleosides, Nucleotides, and Nucleic Acids 26.10-12 (2007): 1543-1546.